



International Regulatory Initiatives to Improve the Delivery of Healthcare in the Fight Against COVID-19

WLG Life Sciences Group



Harry Radomski
Goodmans LLP
Canada



Jonathan Kelp
MinterEllison
Australia



Richard Naiberg
Goodmans LLP
Canada



Helena Nilsson
Setterwalls
Sweden



Expediting the approval of new drugs, vaccines and medical devices, including by relying upon approvals granted in other jurisdictions with comparable regulatory schemes.



Relaxing regulatory and reporting requirements for COVID-19 related drugs, foods and medical devices.



Facilitating cross-border cooperation between regulatory agencies.



Providing mechanisms to identify and remedy shortages in drugs (including disinfectants), foods, personal protective and testing equipment and other necessary items.



Altering the parameters of competition law to permit cooperative work toward COVID-19 related goals among entities who are normally competitors of each other.



Increasing the scrutiny on advertisers of consumer products that make claims related to efficacy for COVID-19.



Providing for compulsory licensing of inventions with application for COVID-19.



Harry Radomski, Goodmans LLP (Canada) – hradomski@goodmans.ca

Jonathan Kelp, MinterEllison (Australia) – jonathan.kelp@minterellison.com

Richard Naiberg, Goodmans LLP (Canada) – rnaiberg@goodmans.ca

Helena Nilsson, Setterwalls (Sweden)– helena.nilsson@setterwalls.se

Thank You!

QUESTIONS?

